Minerva Neurosciences Inc Q2 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Just the first 1 on the potential differences between the placebo response and the Phase IIb and the Phase III. Had the data for a little time now. I'm just wondering whether there's anything that's coming up in this additional data analysis that really point to the reasons why you would have seen a difference. Is it really just the difference in the quality of the clinical sites that you alluded to, Remy, that might be describing that? Or is there something else in the patient demographics that are coming up? I only asked because this is, obviously, something that you're going to be formulating an argument with the FDA about. So just wondering any additional color as to the specific reasons why that differential response may have occurred? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 03, 2020 / 12:30PM, NERV.OQ - Q2 2020 Minerva Neurosciences Inc Earnings Call

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : That's helpful. One final 1 from me. Just in terms of the small amount of patients that have discontinued the open-label extension study due to positive symptom relapse. Maybe in a real-world perspective, would these patients just go on adjunctive therapy with dopamine receptor blockers and they'll be managed there? Or were there something specific in these patients that they must be withdrawn from roluperidone treatment?